CN112626058A - Circumscribed heparinase and application thereof - Google Patents
Circumscribed heparinase and application thereof Download PDFInfo
- Publication number
- CN112626058A CN112626058A CN202011532643.2A CN202011532643A CN112626058A CN 112626058 A CN112626058 A CN 112626058A CN 202011532643 A CN202011532643 A CN 202011532643A CN 112626058 A CN112626058 A CN 112626058A
- Authority
- CN
- China
- Prior art keywords
- heparinase
- exo
- heparin
- exohep
- disaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010022901 Heparin Lyase Proteins 0.000 title claims abstract description 82
- 229960002897 heparin Drugs 0.000 claims abstract description 72
- 229920000669 heparin Polymers 0.000 claims abstract description 68
- 230000000694 effects Effects 0.000 claims abstract description 62
- 102000004190 Enzymes Human genes 0.000 claims abstract description 55
- 108090000790 Enzymes Proteins 0.000 claims abstract description 55
- -1 heparin disaccharide Chemical class 0.000 claims abstract description 29
- 239000000758 substrate Substances 0.000 claims abstract description 24
- 238000005670 sulfation reaction Methods 0.000 claims abstract description 22
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 20
- 230000019635 sulfation Effects 0.000 claims abstract description 17
- 238000012163 sequencing technique Methods 0.000 claims abstract description 14
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 57
- 229920002971 Heparan sulfate Polymers 0.000 claims description 29
- 229920001542 oligosaccharide Polymers 0.000 claims description 14
- 241001496720 Bacteroides intestinalis DSM 17393 Species 0.000 claims description 5
- 230000000593 degrading effect Effects 0.000 claims description 5
- 150000004044 tetrasaccharides Chemical group 0.000 claims description 5
- 241000606125 Bacteroides Species 0.000 claims description 4
- 241000209398 Bacteroides finegoldii DSM 17565 Species 0.000 claims description 4
- 241000304137 Bacteroides thetaiotaomicron VPI-5482 Species 0.000 claims description 4
- 241001566438 Pedobacter arcticus Species 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 229920001499 Heparinoid Polymers 0.000 claims 1
- 239000002554 heparinoid Substances 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 description 51
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000007857 degradation product Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 229910021645 metal ion Inorganic materials 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- PRDZVHCOEWJPOB-IVMDWMLBSA-N N-sulfo-D-glucosamine Chemical compound OC[C@H]1OC(O)[C@H](NS(O)(=O)=O)[C@@H](O)[C@@H]1O PRDZVHCOEWJPOB-IVMDWMLBSA-N 0.000 description 6
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 6
- 125000000600 disaccharide group Chemical group 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 5
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 5
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 5
- 239000012505 Superdex™ Substances 0.000 description 5
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 5
- 239000001099 ammonium carbonate Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002798 spectrophotometry method Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 108010006406 heparinase II Proteins 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- HYZAWROTMYAUAQ-UHFFFAOYSA-N 1-ethyl-3-(6-methylpyridin-2-yl)urea Chemical compound CCNC(=O)NC1=CC=CC(C)=N1 HYZAWROTMYAUAQ-UHFFFAOYSA-N 0.000 description 1
- 241000047484 Bacteroides intestinalis Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102100029001 Heparan sulfate 2-O-sulfotransferase 1 Human genes 0.000 description 1
- 101710096984 Heparan sulfate 2-O-sulfotransferase 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229910020820 NaAc-HAc Inorganic materials 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001660097 Pedobacter Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- ZQOOYCZQENFIMC-STQMWFEESA-N Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)C1=CC=C(O)C=C1 ZQOOYCZQENFIMC-STQMWFEESA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/33—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/74—Optical detectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to an exo-type heparinase and application thereof. The exo-heparinase of the present invention tends to degrade a substrate by sequentially releasing unsaturated disaccharides having specific UV absorption at 232nm from the reducing end. The exo-type heparinase sequentially cuts off the heparin disaccharide with high sulfation degree from the reducing end, and the higher the sulfation degree of the heparin disaccharide, the higher the enzyme activity of the heparinase. In addition, the potential of the excision heparinase in HP/HS structure research is proved by primary sequencing of HP octasaccharide by the excision heparinase exoHep. The invention not only fills the blank of the research field of heparinase, but also provides a novel tool enzyme for the structure and function research and enzymolysis sequencing of HP/HS.
Description
Technical Field
The invention relates to an exo-type heparinase and application thereof, belonging to the technical field of biological enzymes.
Background
Heparin (HP)/Heparan Sulfate (HS) is a polyanionic linear polysaccharide with high heterogeneity of structure, and is an important sulfated glycosaminoglycan. They are widely found on the surface of cell membranes, in the extracellular matrix (ECM) and in the intracellular environment (e.g. mast cells). Due to the existence of a complex and changeable structure, HP/HS can interact with various protein molecules (such as growth factors, morphogen and receptors thereof) and participate in various important physiological and pathological processes such as anticoagulation, cell adhesion, inflammatory reaction, cell migration, cell differentiation, pathogenic microorganism infection, tumorigenesis and development and the like by regulating cell signal transduction, adhesion, migration and the like. These important biological effects have attracted considerable attention to HP/HS and have led to a great deal of research concerning HP/HS structure and function and clinical applications. Since its discovery in 1916, HP and its low-molecular agents have been widely used in clinical treatment as the most important anticoagulants.
The backbone of the HP/HS polysaccharide is composed of repeating disaccharide units composed of D-glucuronic acid or L-iduronic acid (GlcA/IdoA) and N-acetyl-D-glucosamine (GlcNAc). During the biosynthesis of HP/HS, a linear glycan precursor consisting of repeating disaccharide GlcA-GlcNAc units is initially synthesized and then further modified by various modifying enzymes. Wherein the N-deacetylase-N-sulfotransferase and the 3-O-and 6-O-sulfotransferases catalyze sulfation of GlcNAc residues; c5-differentially isomerase catalyzed conversion of GlcA to IdoA residues; and 2-O-sulfotransferase, catalyzing sulfation of GlcA/IdoA residues. These modifications can lead to the presence of a wide variety of disaccharide units in HP/HS polysaccharides, making HP/HS the most complex natural polymer in nature. At the same time, the highly complex structure has severely hampered the study of HP/HS structure and function.
Heparinase (Hepase) of bacterial origin is a polysaccharase that specifically catalyzes the cleavage of the glycosidic bond between GlcNAc and GlcA/IdoA residues in the HP/HS polysaccharide chain by β -elimination, resulting in the production of oligosaccharides containing 4, 5-unsaturated uronic acid residues at the non-reducing end. Heparinase is an essential tool enzyme for the study of HP/HS structure and function. To date, the identified heparinases can be divided into three types according to their substrate specificity: heparinase I (EC 4)2.2.7) that specifically degrade the HP rich in IdoA with a high sulphation degree; heparinase III (EC 4.2.2.8), which tends to degrade low sulphur acidity and GlcA rich HS; heparinase II (EC 4.2.2.-) which can degrade HP and HS simultaneously. The heparinase I protein molecule folds into a beta-jelly roll-type three-dimensional structure, tending to cleave the 1,4 glycosidic bond linked to IdoA2S/GlcA 2S. In contrast, heparinase III consists of one N-terminus (. alpha./alpha.)5Barrel-shaped domain and a C-terminal antiparallel beta sandwich domain, which tends to cleave the 1,4 glycosidic bond to GlcA/IdoA. Heparinase II adopts a topology similar to that of heparinase III and is not selective for a particular GlcA/IdoA or IdoA2S/GlcA2S structure. The three types of heparinase catalytic mechanisms are similar, and all adopt Tyr-His to serve as the catalytic mechanismAcids and bases to catalyze the cleavage of glycosidic bonds.
It is noteworthy that all identified heparinases (HepaseI, II and III) belong to the family of endo-lyases, which randomly cleave glycosidic bonds from within the HP/HS polysaccharide chains, whereas exo-type heparinases, which are urgently needed for HP/HS sugar chain sequencing, have not been discovered and identified.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides an exo-type heparinase and application thereof, and the exo-type heparinase has high-efficiency enzymatic activity for degrading heparin substrates.
The technical scheme adopted by the invention for solving the technical problems is as follows:
an exo-heparinase for sequentially cleaving disaccharide units from the reducing end of a heparin substrate.
Preferably, according to the invention, the heparin substrate is heparin, heparan sulfate or HP-FαIII。
In the present invention, the substrate HP-FαIIIThe HP polysaccharide is completely degraded by Hepase III, then 5 volumes of absolute ethyl alcohol are used for precipitation, and finally the obtained HP oligosaccharide mixture is collected by centrifugation.
Preferably, according to the invention, the disaccharide unit is heparin disaccharide with a high degree of sulfation.
Further preferably, the high-sulfation heparin disaccharide is a disulfated and higher heparin disaccharide.
Further preferably, the degree of sulfation of the tetrasaccharide unit composed of the high-sulfation heparin disaccharide and the heparin disaccharide bonded thereto is at least three-sulfation.
Preferably, according to the invention, the exo-heparinase is the heparinase exoHep, GenBank: EDV07780.1, derived from the strain Bacteroides intestinalis DSM 17393.
Preferably, according to the invention, the exo-heparinase is the heparinase BTexo Hep, GenBank: AAO79757.1, derived from the strain Bacteroides thetaiotaomicron VPI-5482.
Preferably, according to the invention, the exo-heparinase is the heparinase BCexoHep, GenBank: ALJ58962.1, derived from the strain Bacteroides cellulolyticus WH 2.
Preferably, according to the invention, the exo-heparinase is the heparinase BFexoHep from the strain Bacteroides finegoldii DSM 17565, GenBank: EEX 44367.1.
Preferably, according to the invention, the exo-heparinase is a heparinase PAexoHep derived from the strain Pedobacter arcticus, GenBank: WP-026063245.1.
Further preferably, the exo-heparinase exoHep, BCexohep, BTexohep, PAexohep and BFexohep is used for HP-FαIIIThe enzyme activity of the enzyme is 50 plus or minus 15U/mg,62 plus or minus 18U/mg,27 plus or minus 8U/mg,24 plus or minus 7U/mg and 12 plus or minus 4U/mg.
The application of the excision heparinase in the preparation of heparin oligosaccharide.
The application of the excision heparinase in degrading heparin oligosaccharide.
The application of the excision heparinase in heparin oligosaccharide sequencing.
Has the advantages that:
the exo-heparinase of the present invention tends to degrade a substrate by sequentially releasing unsaturated disaccharides having specific UV absorption at 232nm from the reducing end. The exo-type heparinase sequentially cuts off the heparin disaccharide with high sulfation degree from the reducing end, and the higher the sulfation degree of the heparin disaccharide, the higher the enzyme activity of the heparinase. In addition, the potential of the excision heparinase in HP/HS structure research is proved by primary sequencing of HP octasaccharide by the excision heparinase exoHep. The invention not only fills the blank of the research field of heparinase, but also provides a novel tool enzyme for the structure and function research and enzymolysis sequencing of HP/HS.
Drawings
FIG. 1 is a polyacrylamide gel electrophoresis diagram of the expression and purification of heparinase exoHep;
wherein: lane 1, protein molecular weight markers, bands from top to bottom of 120kD, 100kD, 80kD, 60kD, 50kD, 40kD, 30kD, 20kD, 12 kD; lane 2, control bacterial liquid before wall breaking, loading amount 10 μ L, lane 3, bacterial liquid after wall breaking of recombinant bacteria, loading amount 10 μ L, lane 4, supernatant after wall breaking of recombinant bacteria, loading amount 10 μ L, lane 5, exoHep purified by nickel column, loading amount 10 μ L;
FIG. 2 is a graph showing the effect of temperature on the activity of heparinase exoHep; wherein the abscissa is temperature and the ordinate is relative activity;
FIG. 3 is a graph showing the effect of pH on the activity of heparinase exoHep; wherein the abscissa is pH, and the ordinate is relative activity;
FIG. 4 is a graph of the stability effect of temperature on heparinase exoHep; wherein, the abscissa is time, and the ordinate is relative activity;
FIG. 5 is a graph showing the effect of metal ions and chemical agents on the activity of heparinase exoHep; wherein, the abscissa is metal ions and chemical reagents, and the ordinate is relative activity;
FIG. 6 shows Ca2+And Ba2+Curve of the effect of concentration on the activity of heparinase exoHep; wherein the abscissa is Ca2+And Ba2+Concentration, ordinate is relative activity;
FIG. 7 is a High Performance Liquid Chromatography (HPLC) analysis chart of degradation products of heparinase exoHep degrading heparin (a) and heparan sulfate (b); wherein: di is unsaturated heparin disaccharide;
FIG. 8 is a High Performance Liquid Chromatography (HPLC) analysis of degradation products of exo-heparinase exoHep degrading heparin at different times; wherein: di is unsaturated heparin disaccharide;
FIG. 9 is a High Performance Liquid Chromatography (HPLC) analysis of degradation products of saturated heparin 13 sugar by exo-heparinase exoHep at different times; wherein: di is unsaturated heparin disaccharide;
FIG. 10 is a High Performance Liquid Chromatography (HPLC) analysis chart of degradation products of unsaturated heparin hexasaccharide (a) and octasaccharide (b) by exo-heparinase exoHep; wherein: octa: unsaturated heparin octasaccharide; hexa: unsaturated heparin hexasaccharide; di: unsaturated heparin disaccharide;
FIG. 11 is a HPLC analysis chart of re-separation of heparin octasaccharide;
FIG. 12 is a flowchart of the enzymatic sequencing of exo-heparinase exoHep;
FIG. 13 is a sequence result presentation graph of P8-1(a), P8-2(b), P8-3(c), P8-4(d) and P8-5(e), (f) is a disaccharide standard chromatogram; wherein: 3S: Δ UA1-4GlcNAc 3S; 2 SNS: Δ UA2S1-4 GlcNS; NS 6S: Δ UA1-4GlcNS 6S; 2SNS 6S: delta UA2S1-4GlcNS 6S.
Detailed Description
The following examples are set forth so as to provide a thorough disclosure of some of the commonly used techniques of how the present invention may be practiced, and are not intended to limit the scope of the invention. The inventors have made the best effort to ensure accuracy with respect to parameters (e.g., amounts, temperature, etc.) used in the examples, but some experimental errors and deviations should be accounted for. Unless otherwise indicated, molecular weight in the present invention refers to average molecular weight and temperature to degrees celsius.
The source of the biological material is as follows:
the strain of Enterobacter (Bacteroides intestinalis DSM 17393) was purchased from the German Collection of microorganisms and cell cultures.
Substrate HP-FαIIIThe HP polysaccharide is completely degraded by Hepase III, then 5 volumes of absolute ethyl alcohol are used for precipitation, and finally the obtained HP oligosaccharide mixture is collected by centrifugation.
Example 1 extraction of genomic DNA of a Strain of Bacteroides intestinalis DSM 17393
A strain of Bacteroides intestinalis DSM 17393 was inoculated into liquid medium at 37 ℃, 200rpm and anaerobicUnder the condition of shaking culture to OD600Is 1.2; 10mL of the culture broth was centrifuged at 12,000rmp for 25min, and the pellet was collected, washed with 10mL of lysozyme buffer (10mM Tris-HCl pH 8.0), centrifuged at 12,000rpm for 25min, and the pellet was collected.
The liquid culture medium comprises the following components per liter:
5g of tryptone, 5g of peptone, 10g of yeast extract, 5g of beef extract, 5g of glucose and K2HPO42g, Tween-801 mL, cysteine hydrochloride H2O0.5 g, Resazurin 1mg, ddH2O950 mL, vitamin K solution 0.2mL, hemin solution 10mL, buffer S40 mL;
the buffer S comprises the following components per liter:
CaCl2·2H2O 0.25g,MgSO4·7H2O 0.5g,K2HPO4 1g,KH2PO4 1g,NaHCO3 10g,NaCl 2g,ddH2O 1000mL。
in the thallus precipitation, 6.0mL of lysozyme buffer solution is added into each tube to obtain about 7.0mL of bacterial liquid, 280 mu L of lysozyme with the concentration of 20mg/mL is respectively added, and the final concentration is about 800 mu g/mL; after ice bath for 1.0h, warm bath is carried out for 2h at 37 ℃ until the solution is viscous; adding 0.41mL of SDS (sodium dodecyl sulfate) of 100mg/mL and 30 mu L of proteinase K solution of 100mg/mL, and carrying out water bath at 52 ℃ for 1.0 h; adding 7.5mL of Tris-balanced phenol/chloroform/isoamyl alcohol (volume ratio is 25: 24: 1), and slightly inverting and mixing until full emulsification; centrifuging at 4 deg.C for 10min at 10,000g, transferring supernatant, adding 1.0mL NaAc-HAc (pH 5.2, 3.0M) buffer solution and 8.50mL absolute ethanol, and mixing; picking out filamentous DNA with a 1.0mL pipette tip, transferring to a 1.5mL EP centrifuge tube, washing for 2 times with a 70% ethanol solution (stored at-20 ℃) by volume percentage, and discarding the supernatant after microcentrifugation; centrifuging at 4 deg.C for 3min at 10,000g, and thoroughly discarding supernatant; drying the sample in a sterile workbench by blowing air under an alcohol lamp; and (4) resuspending and dissolving the DNA sample by using sterile deionized water, and standing overnight at 4 ℃ to obtain the high molecular weight genome DNA.
Example 2 heparinase-encoding Gene sequences
The genome sequence (GenBank: ABJL02000001.1) of the Enterobacter intestinalis DSM 17393 (Bacteroides intestinalis) already exists in the NCBI database, so that the gene sequences encoding the heparinase exoHep (GenBank: EDV07780.1) are downloaded from the NCBI database without genome resequencing. In addition, we screened some genes with higher similarity to the exoHep from NCBI database and carried out whole gene synthesis, namely heparinase BTexohep derived from strain Bacteroides thetaiotaomicron VPI-5482 (GenBank: AAO79757.1), heparinase BCexohep derived from strain Bacteroides cellulolyticus WH2 (GenBank: ALJ58962.1), heparinase BFexohep derived from strain Bacteroides finegoldii DSM 17565 (GenBank: EEX44367.1) and heparinase PAexohep derived from strain Pedobacter arcticus (GenBank: WP _ 026063245.1).
Example 3 recombinant expression of the ExoHep Gene in E.coli
PCR amplification was performed using the high molecular weight genomic DNA prepared in example 1 as a template.
The PCR primers were as follows:
The restriction sites for restriction enzyme Nde I are underlined for the forward primer, and the restriction sites for restriction enzyme Xho I are underlined for the reverse primer. Primerstar HS DNA polymerase was purchased from Takara Shuzo and the PCR reaction system was performed according to the manufacturer's instructions.
And (3) PCR reaction conditions: pre-denaturation at 95 ℃ for 4 min; denaturation at 95 ℃ for 40s, annealing at 60 ℃ for 40s, extension at 72 ℃ for 2min, and 30 cycles; extension at 72 deg.C for 10min, and stabilization at 4 deg.C for 15 min.
The PCR product was double digested with Nde I and Xho I, and the digested PCR product was recovered by agarose gel electrophoresis. The pET-30a vector purchased from Novagen, USA, was double-digested with Nde I and Xho I, and the large fragment of the digested vector was recovered by agarose gel electrophoresis. Nde I and Xho I are both available from baozoia, and the system, temperature and time of reaction of the enzyme with the substrate are all operated according to the product instructions provided by the company.
Connecting the PCR product subjected to double enzyme digestion with a pET-30a carrier subjected to double enzyme digestion, converting the connection product into an escherichia coli DH5 alpha strain, coating the strain on a Luria-Bertani culture medium solid plate (prepared according to the conventional technology) containing 50 mu g/mL kanamycin, culturing for 14h at 37 ℃, and selecting a monoclonal antibody; inoculating the monoclone into a liquid Luria-Bertani culture medium (prepared according to the conventional technology) containing 50 mu g/mL kanamycin to culture, and extracting plasmids; carrying out bacteria liquid PCR verification on the plasmid by using a forward primer 30aexoHep-F and a reverse primer 30aexoHep-R, obtaining an amplification product with correct size as a result, and preliminarily proving that the constructed recombinant plasmid is correct; the sequencing result of the recombinant plasmid shows that the gene exoHep is inserted between Nde I and Xho I enzyme cutting sites of pET-30a, and the insertion direction is correct, so that the constructed recombinant plasmid is further proved to be correct, and the recombinant plasmid is named as pET30 a-exoHep.
pET30a-exoHep was transformed into E.coli strain BL21(DE3) (available from Novagen, USA), and then inducible expression of recombinant heparinase exoHep was performed according to the procedures provided by the company. And exoHep was purified on Ni Sepharose 6Fast Flow (GE) gel under the conditions according to the product manual of GE. The purification condition of the recombinant heparinase exoHep is detected by 13.2% polyacrylamide gel electrophoresis, and the result is shown in figure 1, the purified recombinant heparinase exoHep is in a single band on the electrophoresis gel, and the position of the recombinant heparinase exoHep is matched with the predicted molecular weight and is 99 kDa.
Example 4 enzymatic Properties analysis of recombinant heparinase exoHep
1. Effect of pH and temperature on enzyme Activity
Heparin with the mass concentration of 1%, exoHep enzyme solution and 150mM NaH2PO4-Na2HPO4(pH 8.0) buffer and water 1: 1: 3: 5 (volume ratio), reacting at different temperatures (0-70 ℃) for 30min, measuring the enzyme activity by an ultraviolet spectrophotometry, and defining the optimal enzyme activity as 100 percent relative activity. The results showed that the exoHep reached maximum activity at 30 ℃, indicating that the optimum reaction temperature for the exoHep was 30 ℃ (see fig. 2).
At the optimum temperature of 30 ℃, the mass concentration is 1 percentHeparin, exoHep enzyme solution, 150mM HA-NaAc, NaH with different pH values2PO4-Na2HPO4Tris-HCl buffer solution (with the pH range of 5.0-10.0) and water, wherein the weight ratio of Tris-HCl buffer solution to water is 1: 1: 3: 5 (volume ratio), reacting for 60min, measuring enzyme activity by ultraviolet spectrophotometry, and defining the optimal enzyme activity as 100% relative activity. The results showed that the exoHep reached maximum activity at pH 6.0, indicating that the optimum reaction pH for the exoHep was 6.0 (see fig. 3).
The ultraviolet spectrophotometry measures the optical density value at the position with the wavelength of 232nm, and determines the enzyme activity by taking the increase of 0.1 per minute of the optical density value as an enzyme activity unit U.
2. Effect of temperature on enzyme stability
The exoHep enzyme solution after heat treatment at 0 ℃, 20 ℃, 30 ℃, 40 ℃, 50 ℃, 60 ℃ and 70 ℃ for different times and the heparin substrate solution with the mass concentration of 1 percent are mixed according to the ratio of 2:3 (volume ratio), and then measuring the residual enzyme activity at the optimal temperature and the optimal pH, wherein the enzyme activity of the enzyme solution without heat treatment is defined as 100 percent relative activity (relative activity), and the result shows that the exoHep still has more than 80 percent of activity after 24 hours at the temperature of 30 ℃ (as shown in figure 4) and has certain thermal stability.
3. Effect of Metal ions on ExoHep Activity
Heparin at a mass concentration of 1%, exoHep enzyme solution, 150mM MAc-NaAc (pH 6.0) buffer solution, and water were mixed in a ratio of 1: 1: 3: 5 (volume ratio), then adding different metal ions into the reaction system, wherein the final concentration of the added ions is 5mM, then reacting for 30min at 30 ℃, and measuring the enzyme activity according to the ultraviolet spectrophotometry. The control group shows the activity of exoHep without any metal ion (set to 100%), and the results are shown in fig. 5. The experimental results show that Ca2+And Ba2+Promoting enzyme activity, and Ag+,Co2+,Hg2+,Pb2+,Ni2+,Cu2+,Zn2+,Fe3+,Cr3+The plasma showed a significant inhibitory effect on enzyme activity (figure 5).
4、Ca2+And Ba2+Effect of concentration on exoHep ActivitySound box
Heparin at a mass concentration of 1%, exoHep enzyme solution, 150mM MAc-NaAc (pH 6.0) buffer solution, and water were mixed in a ratio of 1: 1: 3: 5 (volume ratio), and then adding metal ions Ca of different concentrations to the reaction system2+And Ba2+The final concentrations of the added ions were 0mM, 1mM, 2mM, 5mM, 10mM, and 25mM, and the reaction was carried out at 30 ℃ for 30min, and the enzyme activity was measured by the aforementioned UV spectrophotometry. The control group shows the activity of exoHep without any metal ion (set to 100%), and the results are shown in fig. 6. The results of the experiment show that 5mM Ca2+Can promote 144.69% enzyme activity, and 2mM Ba2+Can promote 122.37% of enzyme activity (figure 6).
Example 5 determination of enzyme Activity of exoHep
Heparin, heparan sulfate or HP-F with the mass concentration of 1 percentαIIIexoHep enzyme solution, 150mM MAc-NaAc (pH 6.0) buffer, and water were mixed at a ratio of 1: 1: 3: 5 (volume ratio), reacting for 1-5 min at the optimum temperature and the optimum pH, measuring the enzyme activity by the ultraviolet spectrophotometry, and simultaneously measuring the protein content of the exoHep enzyme solution by using a protein quantitative kit purchased from Kangji century company, wherein the results show that the specific activity of the exoHep to heparin is 1 +/-0.6U/mg, and the specific activity of the exoHep to the heparin is HP-FαIIIThe specific activity is 50 +/-15U/mg, the heparan sulfate enzyme activity is extremely low, and the detection is difficult, and the exoHep is preliminarily proved to be more prone to degrade the heparin substrate with higher sulfation degree.
Furthermore heparinases BCexohep, BTexohep, PAexohep and BFexohep on HP-FαIIIThe enzyme activity of the enzyme is respectively 62 plus or minus 18U/mg,27 plus or minus 8U/mg,24 plus or minus 7U/mg and 12 plus or minus 4U/mg.
Example 6 high Performance liquid phase (HPLC) analysis of recombinant heparinase exoHep degradation heparin and heparan sulfate degradation products
Mixing 3mg/mL heparin or heparan sulfate, 150mM HA-NaAc (pH 6.0) buffer solution, exoHep enzyme solution and deionized water according to the ratio of 10:10:3:7 (volume ratio), reacting for 12h under the optimal condition, and carrying out HPLC analysis on degradation products, wherein the HPLC analysis conditions are that a gel column: superdex peptide 10/300GL (GE); mobile phase: 0.2M ammonium bicarbonate; flow rate: 0.4 mL/min; detection conditions are as follows: UV232 nm.
As shown in fig. 7, as described in example 5, although the activity of the recombinant heparinase exoHep is very low for heparin and heparan sulfate, under the condition of sufficient reaction, the recombinant heparinase exoHep can still degrade heparin and heparan sulfate, only unsaturated disaccharide is generated, and the activity for heparin is obviously higher than that for heparan sulfate.
Example 7 degradation Pattern of recombinant heparinase exoHep
3mg/mL of heparin, exoHep enzyme solution, 150mM MAc-NaAc (pH 6.0) buffer, and water were mixed in 10:3: 10: 7 (volume ratio), carrying out reaction under the optimal condition, selecting degradation products with different enzymolysis time for HPLC analysis, wherein the HPLC analysis conditions are that a gel column: superdex peptide 10/300GL (GE); mobile phase: 0.2M ammonium bicarbonate; flow rate: 0.4 mL/min; detection conditions are as follows: ex 330nm, Em 420 nm.
The detection result is shown in figure 8, when the exoHep degrades the heparin, only unsaturated disaccharide is always generated, no obvious oligosaccharide with other molecular weight appears, and a few part of oligosaccharide appears in the final product, which indicates that the recombinant heparinase exoHep should be an exonuclease.
Example 8 degradation Direction of recombinant heparinase exoHep
3mg/mL of saturated heparin 13 sugar, exoHep enzyme solution, 150mM MAc-NaAc (pH 6.0) buffer solution and water were mixed in a 10:3: 10: 7 (volume ratio), carrying out reaction under the optimal condition, selecting degradation products with different enzymolysis time for HPLC analysis, wherein the HPLC analysis conditions are that a gel column: superdex peptide 10/300gl (ge); mobile phase: 0.2M ammonium bicarbonate; flow rate: 0.4 mL/min; detection conditions are as follows: ex 330nm, Em 420 nm.
The detection results are shown in FIG. 9, when the exoHep degrades the saturated heparin 13 sugar, only unsaturated disaccharide is always generated, and no oligosaccharide with other molecular weight appears, and the results show that the recombinant heparinase exoHep is an exonuclease and degrades the substrate from the reduction end.
Example 9 recombinant heparinase exoHep oligosaccharide degradation assay
2mg/mL of substrate (heparin octaose, heparin hexaose), 150mM HA-NaAc (pH 6.0) buffer, exoHep enzyme solution and deionized water were mixed at a ratio of 10:2:3:15 (by volume), reacted overnight under optimum conditions, and the degradation products were analyzed by HPLC. HPLC analysis conditions were gel column: superdex peptide 10/300GL (GE); mobile phase: 0.2M ammonium bicarbonate; flow rate: 0.4 mL/min; detection conditions are as follows: UV232 nm.
As shown in FIG. 10, the recombinant heparinase exoHep can degrade heparin hexaose (a) and heparin octaose (b), and can completely degrade into disaccharide, and the residual small part of tetrasaccharide can not degrade, presumably because the residual small part of tetrasaccharide is a resistant structure, such as low sulfation, 3-O-sulfation modification and the like.
Example 10 substrate tendency of recombinant heparinase exoHep
Mu.g of heparin tetrasaccharide substrates of different sulfation patterns (P4-4 (. DELTA. UA1-4GlcNAc6S1-4GlcA1-4GlcNS6S), P4-5 (. DELTA. UA1-4GlcNS1-4GlcA1-4GlcNS6S), P4-6 (. DELTA. UA1-4GlcNS6S1-4GlcA1-4GlcNS6S), P4-7 (. DELTA. UA2S1-4GlcNS6S1-4GlcA1-4GlcNS6S), P4-8 (. DELTA. UA2S1-4GlcNS6S1-4IdoA2S1-4GlcNS6S)), 150 mAc-NaAc (pH 6.0) buffer, exoHep enzyme solution, and deionized water were subjected to HPLC analysis under the conditions of enzyme activity ratio at a volume ratio of mixed enzyme volume ratio of 10:2:3:15, and degradation products were calculated. HPLC analysis conditions were gel column: superdex peptide 10/300GL (GE); mobile phase: 0.2M ammonium bicarbonate; flow rate: 0.4 mL/min; detection conditions are as follows: UV232 nm.
The results show that the enzyme activities of the recombinant heparinase exoHep on P4-4 (trisulfated), P4-5 (trisulfated), P4-6 (tetrasulfated), P4-7 (pentasulfated) and P4-8 (hexasulfated) are respectively 0.5U/mg, 3.89U/mg, 24.22U/mg, 49.12U/mg and 79.49U/mg. This indicates that the enzyme activity of the recombinant heparinase exoHep is gradually increased with the increase of the sulfation degree of the substrate. In contrast, when the total degree of sulfation of heparin tetrasaccharide is either disulfated or monosulfated or even not sulfated, the enzyme activity of the recombinant heparinase exoHep is lower or even non-reactive. This is consistent with the results of the previous example five.
Example 11 sequencing application of recombinant heparinase exoHep
From HP-FαIIIThe prepared HP octaose of defined size was further separated with an ion column and the main peak was recovered. The HPLC separation conditions were: ion column: propack PA 1; mobile phase: 0.5-1.5M NaCl; flow rate: 1 mL/min; separation time: 70 min; detection conditions are as follows: UV232 nm. The main peak was collected and desalted by gel filtration chromatography on a G10 chromatography column.
HPLC separation pattern is shown in FIG. 11, and HP octaose is further divided into five octaose components, P8-1, P8-2, P8-3, P8-4 and P8-5.
Based on the exonuclease characteristic of the recombinant heparinase exoHep, the invention establishes an enzymatic sequencing method, and takes the five octasaccharides as examples, and the steps (figure 12) are as follows:
step 1: 500pmol of five octasaccharides (P8-1, P8-2, P8-3, P8-4 and P8-5) were digested with 50, 9 and 1.5mU of exoHep for 5 minutes, respectively, and UDP6 and UDP4 products were collected and lyophilized repeatedly to remove NH4HCO3Obtaining purified oligosaccharide; wherein, according to the enzyme activities of the exoHep to different substrates, the appropriate enzyme amount corresponding to the corresponding substrate is selected for substrate degradation;
step 2: the UDP8, UDP6 and UDP4 components of each octasaccharide were degraded by heparinase (I, II), labeled with product 2-AB, and then analyzed by HPLC; HPLC analytical conditions were ion column: YMC Pack polyamine II (YMC); mobile phase: 16-550mM sodium dihydrogen phosphate; flow rate: 1 mL/min; analysis time: 60 min; detection conditions are as follows: a fluorescence detector, excitation 330nm, emission 420 nm;
step 3: the non-reducing end of each octasaccharide UDP4 was treated with O3Treatment eliminated non-reducing terminal unsaturated residues, which were then degraded and analyzed as described in Step 2.
The results of HPLC analysis of the above five octasaccharides are shown in FIG. 13. The sequencing analysis process is detailed by taking the sequencing of P8-4 as an example: first, 500pmol of P8-4 was partially degraded with 9mU of exoHep to prepare its non-reducing terminal hexasaccharide (UDP 6)NE-P8-4) And tetrasaccharide (UDP 4)NE-P8-4). HPLC analysis of P8-4(UDP 8)NE-P8-4),UDP6NE-P8-4And UDP4NE-P8-4The disaccharide composition of (2) is shown in FIG. 13d, UDP8NE-P8-4Two unsaturated disaccharides Δ UA1-4GlcNS6S and Δ UA2S1-4GlcNS6S in a molar ratio of 1: 3; these two disaccharides are UDP6NE-P8-4And UDP4NE-P8-4In the molar ratio of 1: 2 and 1: 1. by comparing UDP8NE-P8-4And UDP6NE-P8-4The change in the molar ratio of the middle disaccharides can be concluded that the disaccharide (D) at the reducing end of P8-4 is HexUA2S1-4GlcNS6S, and similarly, the disaccharide at the C-position in P8-4 is determined by comparing UDP6NE-P8-4And UDP4NE-P8-4The disaccharide composition of (a) can be determined as HexUA2S1-4GlcNS 6S. To determine the type of disaccharide at position B in P8-4, O was used3Processing UDP4NE-P8-4To remove unsaturated uronic acid at the non-reducing end and further treated with heparinase (I, II) for disaccharide composition analysis, as shown in FIG. 13d, a single disaccharide peak corresponding to Δ UA2S1-4GlcNS6S was detected, indicating that the disaccharide at the B site is also HexUA2S1-4GlcNS 6S. Finally, based on UDP4NE-P8-4The non-reducing terminal disaccharide (A) of P8-4 was assumed to be. DELTA.UA 1-4GlcNS 6S. In summary, the base sequence of P8-4 can be deduced as Δ UA1-4GlcNS6S1-4HexUA2S1-4GlcNS6S1-4HexUA2S1-4GlcNS6S1-4HexUA2S1-4GlcNS 6S.
By the same method, the base sequences of P-1, P-2, P-3 and P-5 were determined to be Δ UA-4 GlcNS6S-4HexA 2S-4 GlcNS 6-4 HexA 2S-4 GlcNS6S-4HexA 2S-4 GlcNS, Δ UA-4 GlcNS6S-4HexA 2S-4 GlcNS-4HexA 2S-4 GlcNS6S-4HexA 2S-4 GlcNS6, Δ UA-4 GlcNAc 3S-4 HexA 2S-4 GlcNS 6-4 HexA 2S-4 GlcNS6 and Δ UA-4 GlcNAc 3S-4 HexA 2S-4 GlcNS 6-4 HexA 2S-4 GlcNS6S-4 GlcNS 6.
Heparinase BTexoHep (GenBank: AAO79757.1) derived from strain Bacteroides thetaiotaomicron VPI-5482, heparinase BCexoHep (GenBank: ALJ58962.1) derived from strain Bacteroides cellulolyticus WH2, heparinase BFexoHep (GenBank: EEX44367.1) derived from strain Bacteroides finegoldii DSM 17565 and heparinase PAexoHep (GenBank: WP _026063245.1) derived from strain Pedobacter arcus, all confirmed as excising heparinase and all degraded the substrate from the reducing end according to the methods of example 7 and example 8. According to the method of example 9 and example 10, the exo-type heparinase can degrade the substrate with higher sulfation degree like exoHep, and the enzyme activity of the heparinase is gradually improved along with the improvement of the sulfation degree of the substrate. The excision heparinase can be applied to heparin sequencing.
Claims (10)
1. An exo-heparinase for cleaving in sequence a disaccharide unit from the reducing end of a heparin substrate.
2. The exo-heparinase of claim 1 wherein said heparinoid substrate is heparin, heparan sulfate or HP-FαIII。
3. The exo-heparinase of claim 1 wherein said disaccharide unit is high sulphated heparin disaccharide.
4. The exo-heparinase of claim 3 wherein said high sulphation heparin disaccharide is disulphated or higher heparin disaccharide.
5. The exo-heparinase according to claim 3 wherein the degree of sulfation of the tetrasaccharide unit consisting of high-sulfation heparin disaccharide and heparin disaccharide linked thereto is at least three or more times greater than three sulfation.
6. The exo-heparinase of claim 1 wherein the exo-heparinase is the heparinase exoHep derived from strain Bacteroides intestinalis DSM 17393, GenBank: EDV 07780.1;
preferably, the exo-type heparinase is a heparinase BTexo Hep derived from the strain Bacteroides thetaiotaomicron VPI-5482, GenBank: AAO 79757.1;
preferably, the exo-heparinase is a heparinase BCexoHep derived from the strain Bacteroides cellulolyticus WH2, GenBank: ALJ 58962.1;
preferably, the exo-heparinase is a heparinase BFexoHep derived from the strain Bacteroides finegoldii DSM 17565, GenBank: EEX 44367.1;
preferably, the exo-type heparinase is the heparinase PAexoHep derived from the strain Pedobacter arcticus, GenBank: WP-026063245.1.
7. The exo-heparinase of claim 6 wherein said exo-heparinase exoHep, BCexoHep, BTexoHep, paenohep and BFexoHep is on HP-FαIIIThe enzyme activity of the enzyme is 50 plus or minus 15U/mg,62 plus or minus 18U/mg,27 plus or minus 8U/mg,24 plus or minus 7U/mg and 12 plus or minus 4U/mg.
8. Use of the exo-heparinase of claim 1 in the preparation of heparin oligosaccharides.
9. Use of the exo-heparinase of claim 1 for degrading heparin oligosaccharides.
10. Use of the exo-heparinase of claim 1 in heparin oligosaccharide sequencing.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011532643.2A CN112626058B (en) | 2020-12-22 | 2020-12-22 | Circumscribed heparinase and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011532643.2A CN112626058B (en) | 2020-12-22 | 2020-12-22 | Circumscribed heparinase and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112626058A true CN112626058A (en) | 2021-04-09 |
CN112626058B CN112626058B (en) | 2022-09-27 |
Family
ID=75321235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011532643.2A Active CN112626058B (en) | 2020-12-22 | 2020-12-22 | Circumscribed heparinase and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112626058B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113884588A (en) * | 2021-09-03 | 2022-01-04 | 中国计量科学研究院 | Method for detecting activity of differential isomerase of glucuronic acid C5 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1429913A (en) * | 2001-12-30 | 2003-07-16 | 中国科学院微生物研究所 | Method of producing heparin oligosaccharide using heparinase |
US20050065738A1 (en) * | 2003-09-04 | 2005-03-24 | Parivid Llc | Methods and apparatus for characterizing polymeric mixtures |
CN1934135A (en) * | 2004-03-24 | 2007-03-21 | 艾文蒂斯药品公司 | Method for quantitatively determining specific constituting heparins or low molecular weight heparins using hplc |
CN102277396A (en) * | 2010-06-13 | 2011-12-14 | 黄欣 | Preparation method and application of heparin oligosaccharide with specific length |
CN104792896A (en) * | 2015-04-23 | 2015-07-22 | 苏州融析生物科技有限公司 | Heparanase composition capable of complete specific enzymolysis of enoxaparin sodium and application of heparanase composition |
-
2020
- 2020-12-22 CN CN202011532643.2A patent/CN112626058B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1429913A (en) * | 2001-12-30 | 2003-07-16 | 中国科学院微生物研究所 | Method of producing heparin oligosaccharide using heparinase |
US20050065738A1 (en) * | 2003-09-04 | 2005-03-24 | Parivid Llc | Methods and apparatus for characterizing polymeric mixtures |
CN1934135A (en) * | 2004-03-24 | 2007-03-21 | 艾文蒂斯药品公司 | Method for quantitatively determining specific constituting heparins or low molecular weight heparins using hplc |
CN102277396A (en) * | 2010-06-13 | 2011-12-14 | 黄欣 | Preparation method and application of heparin oligosaccharide with specific length |
CN104792896A (en) * | 2015-04-23 | 2015-07-22 | 苏州融析生物科技有限公司 | Heparanase composition capable of complete specific enzymolysis of enoxaparin sodium and application of heparanase composition |
Non-Patent Citations (7)
Title |
---|
FULTON,L. ET AL.: ""heparinase II/III-like protein [Bacteroides finegoldii DSM 17565], EEX44367.1", 《GENBANK》 * |
GENBANK: "DUF4962 domain-containing protein [Pedobacter arcticus],WP_026063245.1", 《GENBANK》 * |
QINGDONG ZHANG ET AL.: "Discovery of exolytic heparinases and their catalytic mechanism and potential application", 《NATURE COMMUNICATIONS》 * |
SUDARSANAM,P. ET AL.: "heparinase II/III-like protein [Bacteroides intestinalis DSM 17393],EDV07780.1", 《GENBANK》 * |
WU,M. ET AL.: "Heparin and heparin-sulfate lyase precursor [Bacteroides cellulosilyticus] ,ALJ58962.1", 《GENBANK》 * |
XU,J. ET AL.: "Oligosaccharide lyase [Bacteroides thetaiotaomicron VPI-5482],AAO79757.1", 《GENBANK》 * |
刘文丽等: "肝素酶在医药领域应用的研究进展", 《生物工程学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113884588A (en) * | 2021-09-03 | 2022-01-04 | 中国计量科学研究院 | Method for detecting activity of differential isomerase of glucuronic acid C5 |
Also Published As
Publication number | Publication date |
---|---|
CN112626058B (en) | 2022-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008207616B2 (en) | Heparin/heparosan synthase and methods of making and using same | |
CN106811454B (en) | Truncated recombinant alginate lyase rAly1-T185N and coding gene and application thereof | |
EP3399044B1 (en) | Method for producing heparan sulfate having anticoagulant activity | |
CN112251426B (en) | Chondroitin sulfate lyase, and coding gene and application thereof | |
JP2008512105A (en) | Method for producing K5 polysaccharide | |
Muñoz et al. | Enzymatic synthesis of heparin related polysaccharides on sensor chips: rapid screening of heparin–protein interactions | |
CN113583151A (en) | Heparin molecule containing AT binding sequence and continuous 2-O-glucuronic acid residue, and preparation method and application thereof | |
EP1282684B1 (en) | Chondroitin synthase gene and methods of making and using same | |
CN112626058B (en) | Circumscribed heparinase and application thereof | |
Manns et al. | Impact of different alginate lyases on combined cellulase–lyase saccharification of brown seaweed | |
CN108048435B (en) | Incision type bifunctional alginate lyase Aly2 for generating various monosaccharide products, and coding gene and application thereof | |
CN111454974B (en) | Endo-type beta-mannanohydrolase Man01929, method for mutating same into glycosyltransferase and application of endo-type beta-mannanohydrolase Man01929 | |
CN110951803B (en) | Method for preparing neoagarobiose by combined utilization of agarase, recombinant host cell and application of recombinant host cell and expression vector | |
AU2001253805A1 (en) | Chondroitin synthase gene and methods of making and using same | |
CN110951805B (en) | Enzymolysis preparation method of low molecular weight laver polysaccharide and laver oligosaccharide | |
CN109628426B (en) | Delta 4, 5-hexuronic acid-2-O-sulfatase, encoding gene and application thereof, and identification method of homologous enzyme | |
CN110511918B (en) | Alginate lyase system and application thereof | |
US20040197868A1 (en) | Heparin/heparosan synthase from P. multocida, soluble and single action catalysts thereof and methods of making and using same | |
Zhang et al. | Uncovering the detailed mode of cleavage of heparinase I toward structurally defined heparin oligosaccharides | |
CN110408566B (en) | Externally tangent chondroitin sulfate degrading enzyme and coding gene and application thereof | |
CN105713890A (en) | Exo-GAG (glycosaminoglycan) lyase as well as encoding gene and application thereof | |
CN110055234B (en) | Chondroitin sulfate synthase and coding gene and application thereof | |
CN113136380B (en) | Broad-spectrum polysaccharide degrading enzyme rAly16-1 from streptomyces as well as coding gene and application thereof | |
CN113999830B (en) | Ocean-derived externally-tangent chondroitin sulfate sulfatase, and coding gene and application thereof | |
US11932881B2 (en) | Heparin skeleton synthase and its mutants and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |